[
  {
    "ts": null,
    "headline": "Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $250.00. AbbVie Inc. (NYSE:ABBV) reported positive fiscal Q1 2025 results that support the optimistic outlook, with adjusted […]",
    "url": "https://finnhub.io/api/news?id=1f49ad372bff86b9c652217ed5377da95ed3e8d65bcaa30a2c9999f9a6785ded",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752986116,
      "headline": "Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT",
      "id": 136019739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $250.00. AbbVie Inc. (NYSE:ABBV) reported positive fiscal Q1 2025 results that support the optimistic outlook, with adjusted […]",
      "url": "https://finnhub.io/api/news?id=1f49ad372bff86b9c652217ed5377da95ed3e8d65bcaa30a2c9999f9a6785ded"
    }
  }
]